How to buy Bionomics (BNO) shares

Learn how to easily invest in Bionomics shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Bionomics is a biotechnology business based in Australia. Bionomics shares (BNO) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Bionomics has a trailing 12-month revenue of around $928,073. If you're looking to buy shares, check out the steps below.

How to buy shares in Bionomics

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Bionomics. Find the share by name or ticker symbol: BNO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bionomics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Bionomics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bionomics stock price (ASX:BNO)

Use our graph to track the performance of BNO stocks over time.

Bionomics shares at a glance

Information last updated 2022-01-15.
52-week range$0.089 - $0.485
50-day moving average $0.1148
200-day moving average $0.1671
Target price$0.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.011

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
ThinkMarkets Share Trading
AUD $8
No
ASX shares
$8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
Superhero share trading
$5
No
ASX shares, US shares, ETFs
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
GO Markets Share Trading
$7.70
No
ASX shares, Forex, CFDs, ETFs
Pay zero brokerage on your first 20 trades and $7.70 after that on over 2,500 ASX listed shares from either your desktop or mobile.
Opentrader Share Trading
AUD $5
No
ASX shares, Options trading, ETFs, Warrants
Gain access to chess sponsored shares for as little as $5 per trade.
Get free live data, advanced charting and even gain experience before trading through fantasy portfolios when you sign up with OpenTrader.
Saxo Capital Markets (Classic account)
AUD $5
No
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
HSBC Online Share Trading
AUD $19.95
No
ASX shares, mFunds, ETFs, Bonds
Limited-time offer: Join HSBC’s online trading account before 28 February 2022 and HSBC will reimburse you up to $100 on your first 5 trades. Also traders who transfer $50k+ will get a $200 bonus(T&Cs apply).
Make trades online with brokerage fees starting from just $19.95 with an HSBC Online Share Trading account. Plus gain access to complimentary expert research, trading ideas and tools.
SelfWealth (Basic account)
AUD $9.5
No
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
loading

Compare up to 4 providers

Is it a good time to buy Bionomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bionomics price performance over time

Historical closes compared with the last close of A$0.11

1 week (2022-01-12) 10.00%
1 month (2021-12-17) -18.52%
3 months (2021-10-19) -26.67%
6 months (2021-07-19) -42.11%
1 year (2021-01-19) -33.33%
2 years (2020-01-17) 37.50%
3 years (2019-01-18) -12.00%
5 years (2017-01-19) -69.44%

Is Bionomics under- or over-valued?

Valuing Bionomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bionomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bionomics's EBITDA

Bionomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $255,158 (£134,846).

The EBITDA is a measure of a Bionomics's overall financial performance and is widely used to measure a its profitability.

Bionomics financials

Revenue TTM $928,073
Gross profit TTM $-4,834,230
Return on assets TTM -14.48%
Return on equity TTM -28.86%
Profit margin 0%
Book value 0.047
Market capitalisation $142.1 million

TTM: trailing 12 months

Bionomics share dividends

We're not expecting Bionomics to pay a dividend over the next 12 months.

Have Bionomics's shares ever split?

Bionomics's shares were split on 1 March 2004.

Bionomics share price volatility

Over the last 12 months, Bionomics's shares have ranged in value from as little as $0.089 up to $0.485. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Bionomics's is 2.6209. This would suggest that Bionomics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Bionomics overview

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site